Contextual Genomics Inc. and Sonic Healthcare Limited announced they have signed an agreement enabling Sonic to provide quality-assured Next Generation Sequencing (NGS)-based genetic testing to cancer patients in Australia and other parts of the world. Under the terms of the distribution, license and services agreement, Sonic will offer Find-It, a molecular test for solid tumor cancers, at its laboratories to patients diagnosed with cancer. The Find-It hotspot assay screens for known gene mutations found in solid tumor cancers, most of which are treatable with current therapies or Phase 3 investigational treatments. The Find-It assay helps to identify optimal therapeutic treatments for patients, recognize acquired drug-resistant mutations, as well as determine prognostic and diagnostic implications for patient care. Under the agreement, Sonic will have access to Contextual’s proprietary bioinformatics molecular analysis technology and quality control systems (QA Nexus™ suite) and Contextual will have access to Sonic’s federated structure of medically-led practices.